SI0792149T1 - Oral compositions containing ondansetron - Google Patents

Oral compositions containing ondansetron

Info

Publication number
SI0792149T1
SI0792149T1 SI9530444T SI9530444T SI0792149T1 SI 0792149 T1 SI0792149 T1 SI 0792149T1 SI 9530444 T SI9530444 T SI 9530444T SI 9530444 T SI9530444 T SI 9530444T SI 0792149 T1 SI0792149 T1 SI 0792149T1
Authority
SI
Slovenia
Prior art keywords
pct
compositions containing
oral compositions
sec
pharmaceutically acceptable
Prior art date
Application number
SI9530444T
Other languages
English (en)
Inventor
Renu Gambhir
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10764811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI0792149(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Publication of SI0792149T1 publication Critical patent/SI0792149T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Dental Preparations (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
SI9530444T 1994-11-22 1995-11-20 Oral compositions containing ondansetron SI0792149T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9423588A GB9423588D0 (en) 1994-11-22 1994-11-22 Compositions
EP95941825A EP0792149B1 (en) 1994-11-22 1995-11-20 Oral compositions containing ondansetron
PCT/IB1995/001152 WO1996015786A2 (en) 1994-11-22 1995-11-20 Oral compositions containing ondansetron

Publications (1)

Publication Number Publication Date
SI0792149T1 true SI0792149T1 (en) 2001-02-28

Family

ID=10764811

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9530444T SI0792149T1 (en) 1994-11-22 1995-11-20 Oral compositions containing ondansetron

Country Status (32)

Country Link
US (1) US5854270A (instruction)
EP (1) EP0792149B1 (instruction)
JP (1) JP2965704B2 (instruction)
KR (1) KR100292124B1 (instruction)
CN (1) CN1108153C (instruction)
AT (1) ATE196084T1 (instruction)
AU (1) AU703932B2 (instruction)
BE (1) BE1009458A5 (instruction)
BR (1) BR9509807A (instruction)
CA (1) CA2205546C (instruction)
CY (1) CY2171B1 (instruction)
CZ (1) CZ285187B6 (instruction)
DE (1) DE69518767T2 (instruction)
DK (1) DK0792149T3 (instruction)
ES (1) ES2151083T3 (instruction)
FI (1) FI119356B (instruction)
FR (1) FR2727015B1 (instruction)
GB (2) GB9423588D0 (instruction)
GR (1) GR3034684T3 (instruction)
HU (1) HU226947B1 (instruction)
IE (1) IE950884A1 (instruction)
IL (1) IL116083A (instruction)
IT (1) IT1282353B1 (instruction)
NO (1) NO306892B1 (instruction)
NZ (1) NZ297879A (instruction)
PL (1) PL181522B1 (instruction)
PT (1) PT792149E (instruction)
RU (1) RU2145853C1 (instruction)
SI (1) SI0792149T1 (instruction)
TW (1) TW413634B (instruction)
WO (1) WO1996015786A2 (instruction)
ZA (1) ZA959820B (instruction)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2162561B1 (es) * 1999-06-28 2002-07-16 Boehringer Ingelheim Espana Composicion farmaceutica de metamizol oral, liquida, transparente, estable y de sabor aceptable.
US6473876B1 (en) 1999-06-29 2002-10-29 Sony Corporation Method and apparatus for encoding of bitstreams using rotation
EP1206264A2 (en) * 1999-08-25 2002-05-22 Barrett R. Cooper Compositions and methods for treating opiate intolerance
RU2162695C1 (ru) * 2000-07-14 2001-02-10 ООО с иностранными инвестициями "Редди-Биомед лимитед" Способ получения ондансетрона гидрохлорида дигидрата, субстанция и фармацевтический препарат
HUP0401239A2 (hu) * 2000-10-30 2004-12-28 Teva Pharmaceutical Industries Ltd. Ondansetron-hidroklorid új kristályos és szolvát formái, valamint eljárások az előállításukra
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
MXPA04009968A (es) * 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
CN1665823A (zh) * 2002-04-29 2005-09-07 特瓦药厂有限公司 制备1,2,3,9－四氢－9－甲基－3－[(2－甲基－1h－咪唑－1－基)甲基]－4h－咔唑－4－酮的方法
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
EP1465887A1 (en) * 2002-04-30 2004-10-13 Teva Gyogyszergyar Reszvenytarsasag Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
DE10393729T5 (de) * 2002-11-15 2005-10-13 Helsinn Healthcare S.A. Verfahren zur Behandlung von Emesis
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JP2006028028A (ja) * 2004-07-12 2006-02-02 Teikoku Medix Kk 経口医薬組成物
CN100423779C (zh) * 2006-09-27 2008-10-08 中国药科大学 一种以5－羟色胺3受体拮抗剂和h2受体拮抗剂为活性成分的药用组合物及其制药用途
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
CA3066426A1 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US20110201597A1 (en) * 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
US8877768B2 (en) 2009-09-18 2014-11-04 Chase Pharmaceuticals Corporation Method and composition for treating alzheimer-type dementia
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US20110288115A1 (en) * 2010-05-24 2011-11-24 Avmedis Llc Treatment of vagally-mediated spectrum disorders
US20120302616A1 (en) * 2010-12-03 2012-11-29 Nikhilesh Singh Method of treatment of obsessive compulsive disorder with ondansetron
KR101058749B1 (ko) * 2010-12-29 2011-08-24 에스씨바이오팜 주식회사 네오헤스피리딘 디하이드로찰콘을 감미료로 사용하는 온단세트론 염산염 이수화물 함유 액상 조성물
BR112015004902A2 (pt) 2012-09-05 2017-07-04 Chase Pharmaceuticals Corp métodos e composição neutroprotetores anticolinérgicos
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
KR101635820B1 (ko) * 2015-10-30 2016-07-04 재단법인 통합의료진흥원 온단세트론 및 반하후박탕을 포함하는 항암치료 보조용 조성물
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
KR101721094B1 (ko) * 2016-09-09 2017-03-29 재단법인 통합의료진흥원 댕댕이나무 열매 추출물을 포함하는 오심 및 구토 치료 효과 증진용 조성물
KR102675602B1 (ko) * 2023-09-01 2024-06-14 (주)옥천당 항암제 투여시 유발되는 소화관 장애의 효과적 제어가 가능한 신규 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2561244B1 (fr) * 1984-01-25 1988-03-04 Glaxo Group Ltd Composes heterocycliques du type tetrahydrocarbazolone, procede pour leur preparation et composition pharmaceutique les comprenant
EP0385517B1 (en) * 1985-03-14 1993-04-14 BEECHAM GROUP plc Medicaments for the treatment of emesis
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
EP0450757A3 (en) * 1990-02-22 1993-09-15 Glaxo Group Limited Use of 5-hydroxytryptamine-antagonists in the treatment of mental disorders originating in childhood
ITMI922854A1 (it) * 1992-12-15 1994-06-15 Boehringer Ingelheim Italia Uso degli antagonisti dei recettori 5-ht3

Also Published As

Publication number Publication date
PL181522B1 (en) 2001-08-31
CZ154897A3 (en) 1997-10-15
JP2965704B2 (ja) 1999-10-18
PT792149E (pt) 2001-02-28
CA2205546C (en) 2000-01-25
FI972168L (fi) 1997-05-21
RU2145853C1 (ru) 2000-02-27
CY2171B1 (en) 2002-08-23
NO972324D0 (no) 1997-05-21
EP0792149A2 (en) 1997-09-03
KR100292124B1 (ko) 2001-07-12
JPH10508866A (ja) 1998-09-02
NO306892B1 (no) 2000-01-10
GB9423588D0 (en) 1995-01-11
WO1996015786A3 (en) 1996-06-27
ES2151083T3 (es) 2000-12-16
HUT77944A (hu) 1998-12-28
GR3034684T3 (en) 2001-01-31
CZ285187B6 (cs) 1999-06-16
KR970706815A (ko) 1997-12-01
AU4313596A (en) 1996-06-17
ATE196084T1 (de) 2000-09-15
BR9509807A (pt) 1997-10-21
IE950884A1 (en) 1996-05-29
US5854270A (en) 1998-12-29
FI972168A0 (fi) 1997-05-21
IL116083A (en) 2000-09-28
FR2727015A1 (fr) 1996-05-24
FR2727015B1 (fr) 1997-08-22
CN1171740A (zh) 1998-01-28
GB2295317A (en) 1996-05-29
DE69518767T2 (de) 2001-05-31
ZA959820B (en) 1996-07-29
TW413634B (en) 2000-12-01
ITRM950763A0 (instruction) 1995-11-20
CN1108153C (zh) 2003-05-14
MX9703734A (es) 1997-09-30
CA2205546A1 (en) 1996-05-30
HK1009590A1 (en) 1999-06-04
HU226947B1 (en) 2010-03-29
FI119356B (fi) 2008-10-31
IT1282353B1 (it) 1998-03-20
IL116083A0 (en) 1996-01-31
GB9523666D0 (en) 1996-01-24
EP0792149B1 (en) 2000-09-06
GB2295317B (en) 1998-11-25
AU703932B2 (en) 1999-04-01
NO972324L (no) 1997-07-21
DK0792149T3 (da) 2000-12-18
PL320288A1 (en) 1997-09-15
NZ297879A (en) 1998-12-23
DE69518767D1 (de) 2000-10-12
ITRM950763A1 (it) 1997-05-20
BE1009458A5 (fr) 1997-04-01
WO1996015786A2 (en) 1996-05-30

Similar Documents

Publication Publication Date Title
GB2295317B (en) Liquid composition containing ondansetron
GB2295318B (en) Freeze-dried dosage form containing ondansetron
DK0772441T3 (da) Progesteronantagonist og gestagen til behandling af endometriose og leiomyomata
IL113566A0 (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
BG105534A (en) 5ht1 means and method for the treatment of migraine
HUT77611A (hu) Eljárás dózisegységek előállítására nedves granulálással
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine